What Can We Help You Find?

Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

05/18
2020

Coronavirus and Lung Cancer: Joint Statement From Lung Cancer Advocacy Groups

Lung Cancer Foundation of America (LCFA) and our sister lung cancer advocacy organizations are issuing regular joint statements on coronavirus and lung cancer to help people understand what is known about the disease, find reliable sources…

05/12
2020

End the Debate on Biomarker Testing for NSCLC

From Lung Cancer News Benefits of Biomarker Testing It’s an exciting time to be a thoracic oncologist. We live in an era of unprecedented discovery in medicine—and in oncology in particular—with basic scientific breakthroughs s…

05/8
2020

African Americans and Lung Cancer Screening

From Lung Cancer News Lung cancer screening, which includes a shared decision-making visit and low-dose computed tomography (CT) scan of the chest, is fully covered for those who meet eligibility criteria by Affordable Care Act complian…

05/5
2020

Lung Cancer Treatment Progress Over the Last Decade

From IASLC Lung Cancer News After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field of lung cancer research. Lung Cancer treatment progress ga…

04/23
2020

Immunotherapy and BMI

From Cure Magazine Immunotherapy and BMI Patients with non-small cell lung cancer who have a high body mass index (BMI) have improved survival outcomes when they receive immunotheraapy (immune checkpoint inhibitor therapy), according…

04/23
2020

Testing Patients with Lung Cancer for COVID-19

From Cancer Network In an article that will appear in Annals of Oncology, researchers outlined recommendations for testing patients with lung cancer for the coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by t…

04/16
2020

Conducting Clinical Trials During Coronavirus Pandemic

The U.S. Food and Drug Administration today issued a guidance for industry, investigators and institutional review boards conducting clinical trials during the coronavirus (COVID-19) pandemic. Impact of Coronavirus on Clinical…

04/16
2020

Does Delaying ALK+ Treatment Impact Survival?

From the Journal Lung Cancer What effect does delaying ALK+ treatment have on survival? Several obstacles may result in delaying ALK+ treatment in patients with anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (N…

04/16
2020

Durvalumab Approved for SCLC

From Targeted Oncology The FDA has approved durvalumab (Imfinzi) in combination with standard-of-care chemotherapy, etoposide and carboplatin or cisplatin, as a frontline treatment for adult patients with extensive-stage small c…

03/31
2020

African American Lung Cancer Patients less likely to receive lung cancer imaging

From Medical Express African American Lung Cancer Patients and PET-CT imaging The use of PET-CT imaging gives doctors the best possible picture of non-small cell lung cancer (NSCLC), and this accurate imaging helps to match patients …

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson